Is Solara Active Pharma Sciences a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Solara Active Pharma Sciences Ltd is a below average quality company .

Is Solara Active Pharma Sciences undervalued or overvalued?

The key valuation ratios of Solara Active Pharma Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Solara Active Pharma Sciences share price return in the past 10 years?

Data is not available for this company

Is Solara Active Pharma Sciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Solara Active Pharma Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Solara Active Pharma Sciences?

The latest standalone P/E ratio of Solara Active Pharma Sciences as of 21-Nov-2024 is 0.00.

What is the P/B ratio of Solara Active Pharma Sciences?

The latest standalone P/B ratio of Solara Active Pharma Sciences as of 21-Nov-2024 is 3.33.

What is the 52-week high and low of Solara Active Pharma Sciences?

The 52-week high of Solara Active Pharma Sciences is Rs. 850.05 and the 52-week low is Rs. 292.16.

Solara Active Pharma Sciences Ltd - Stock Valuation and Financial Performance

Name: Solara Active Pharma Sciences
Brand: Solara Active Pharma Sciences

BSE: 541540 | NSE: SOLARA | Pharmaceuticals & Drugs | Small Cap

Place order

Solara Active Pharma Share Price

₹761.25 -0.65 -0.09%
as on 21-Nov'24 16:59

10 Year X-Ray of Solara Active Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	0%	0%	0%	2.2%	10.4%	11.7%	15.3%	-0.7%	1.8%	-17.3%	-
Value Creation Index ⓘ	NA	NA	NA	-0.8	-0.3	-0.2	0.1	-1.1	-0.9	-2.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	0	521	1,387	1,322	1,617	1,268	1,444	1,289	1,259
Sales YoY Gr.	-	NA	NA	NA	166.2%	-4.7%	22.3%	-21.6%	13.8%	-10.7%	-
Adj EPS ⓘ	0	0	0	2.2	26.4	38.1	56.7	-15.3	-5.8	-111.5	-111.6
YoY Gr.	-	NA	NA	NA	1087.8%	44.4%	48.9%	-127%	NA	NA	-
BVPS (₹) ⓘ	0	0	0	285.4	303.8	338.2	406.5	390.1	383.8	238.7	227.9
Adj Net Profit ⓘ	0	0	0	6	73.8	111	221	-59.6	-22.6	-435	-536
Cash Flow from Ops. ⓘ	0	0	0	49.2	166	242	155	-242	156	109	-
Debt/CF from Ops. ⓘ	0	0	0	12.9	3.2	2.9	3.9	-4.2	6.4	9.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	-1.5%	-7.3%	-10.7%
Adj EPS ⓘ	NA	-233.4%	-225.3%	NA
BVPSⓘ	NA	-4.7%	-16.3%	-37.8%
Share Price	-	12.4%	-7.5%	146.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	0.8	8.6	10.9	16.5	-3.8	-1.5	-35.8	-47.8
Op. Profit Mgn % ⓘ	12	16.6	19.8	24	6.4	9.3	-7.4	-3.9
Net Profit Mgn % ⓘ	1.1	5.3	8.4	13.7	-4.7	-1.6	-33.7	-42.6
Debt to Equity ⓘ	0.8	0.6	0.7	0.4	0.7	0.7	1.1	0.1
Working Cap Days ⓘ	0	163	177	178	312	310	285	109
Cash Conv. Cycle ⓘ	0	40	64	70	189	194	181	-52

Recent Performance Summary

No data to display

Return on Equity is Poor

Sales growth has been subdued in last 3 years -7.28%

Debt to equity has increased versus last 3 years average to 1.07

Sales growth is not so good in last 4 quarters at -18.39%

Latest Financials - Solara Active Pharma Sciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-111.6	-111.6
TTM Sales (₹ Cr.)	1,259	1,259
BVPS (₹.) ⓘ	228.9	227.9
Reserves (₹ Cr.) ⓘ	1,052	1,047
P/BV ⓘ	3.33	3.34
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	292.16 / 850.05
All Time Low / High (₹)	123.04 / 1713.61
Market Cap (₹ Cr.)	3,661
Equity (₹ Cr.)	48.1
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Solara Active Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

27.98

28.18

33.73

40.46

39.79

43.47

49.06

47.99

38.28

38.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Solara Active Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Solara Active Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	521	1,387	1,322	1,617	1,268	1,444	1,289
Operating Expenses ⓘ	458	1,166	1,062	1,231	1,188	1,310	1,384
Manufacturing Costs	79	181	172	181	194	200	233
Material Costs	272	705	599	724	654	789	805
Employee Cost	69	186	204	229	236	229	244
Other Costs ⓘ	39	94	87	96	104	93	103
Operating Profit ⓘ	62	221	259	386	80	134	-95
Operating Profit Margin (%)	12.0%	15.9%	19.6%	23.9%	6.3%	9.3%	-7.4%
Other Income ⓘ	2	12	28	29	20	23	5
Interest ⓘ	25	82	78	84	75	90	105
Depreciation ⓘ	34	83	94	109	112	111	103
Exceptional Items ⓘ	0	0	0	0	-3	0	-190
Profit Before Tax ⓘ	6	68	115	222	-91	-45	-488
Tax ⓘ	0	1	0	0	-33	-23	79
Profit After Tax	6	67	115	221	-58	-22	-567
PAT Margin (%)	1.1%	4.8%	8.7%	13.7%	-4.6%	-1.5%	-44.0%
Adjusted EPS (₹)	0.1	21.3	39.3	56.8	-14.9	-5.7	-145.0
Dividend Payout Ratio (%)	0%	22%	5%	11%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	764	849	985	1,585	1,524	1,499	932
Share Capital ⓘ	25	26	27	36	36	36	36
Reserves ⓘ	739	824	958	1,549	1,488	1,463	896
Minority Interest	4	4	4	4	2	2	3
Debt	573	439	587	516	893	884	866
Long Term Debt	243	225	233	155	283	235	106
Short Term Debt	330	214	354	361	610	649	760
Trade Payables	313	244	216	309	276	306	313
Others Liabilities ⓘ	167	422	361	174	195	130	237
Total Liabilities ⓘ	1,821	1,960	2,153	2,588	2,890	2,821	2,351
Fixed Assets
Gross Block	1,100	1,309	1,581	1,675	1,760	1,868	1,876
Accumulated Depreciation	36	121	213	318	429	528	611
Net Fixed Assetsⓘ	1,063	1,189	1,368	1,356	1,332	1,340	1,266
CWIP ⓘ	71	40	40	88	239	238	256
Investmentsⓘ	1	0	0	0	0	2	2
Inventories	188	214	280	295	576	558	360
Trade Receivables	263	289	227	484	490	537	349
Cash Equivalents	47	76	57	199	47	9	9
Others Assetsⓘ	189	151	181	166	206	137	111
Total Assets ⓘ	1,821	1,960	2,153	2,588	2,890	2,821	2,351

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	49	166	242	155	-242	156	109
PBT ⓘ	0	58	115	222	-91	-45	-488
Adjustment ⓘ	63	148	168	173	181	187	406
Changes in Working Capital ⓘ	-11	-25	-16	-206	-314	1	191
Tax Paid ⓘ	-3	-14	-24	-33	-18	14	1
Cash Flow From Investing Activity ⓘ	-85	-116	-359	-106	-243	-81	-4
Capex	-35	-58	-268	-172	-208	-110	-40
Net Investments	0	47	-50	50	0	-1	0
Others ⓘ	-51	-104	-41	15	-34	30	37
Cash Flow From Financing Activityⓘ	68	-23	97	92	334	-113	-106
Net Proceeds from Shares ⓘ	0	44	30	298	3	0	0
Net Proceeds from Borrowing ⓘ	53	21	34	-107	169	-62	-114
Interest Paid ⓘ	-22	-78	-79	-83	-73	-87	-103
Dividend Paid ⓘ	0	0	-16	-20	-11	0	0
Others ⓘ	37	-11	128	4	246	37	111
Net Cash Flow ⓘ	31	27	-20	142	-151	-38	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	0.78	8.32	12.48	17.23	-3.75	-1.47	-46.64
ROCE (%)	2.22	10.38	11.73	15.34	-0.67	1.79	-17.29
Asset Turnover Ratio	0.29	0.73	0.64	0.68	0.46	0.51	0.5
PAT to CFO Conversion(x)	8.17	2.48	2.1	0.7	N/A	N/A	N/A
Working Capital Days
Receivable Days	184	73	71	80	140	130	125
Inventory Days	131	53	68	65	125	143	130
Payable Days	420	144	140	132	163	135	140

Solara Active Pharma Sciences Ltd Stock News

Solara Active Pharma Sciences Ltd FAQs

What is the share price of Solara Active Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Solara Active Pharma on 21-Nov-2024 16:59 is ₹761.2.

What is the market cap of Solara Active Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Solara Active Pharma stood at ₹3,661.2.

What is the P/E ratio of Solara Active Pharma?

The latest P/E ratio of Solara Active Pharma as of 21-Nov-2024 16:59 is 0.00.

What is the P/B ratio of Solara Active Pharma?

The latest P/B ratio of Solara Active Pharma as of 21-Nov-2024 16:59 is 3.33.

What is the 52-week high and low of Solara Active Pharma?

The 52-week high of Solara Active Pharma is ₹850.0 and the 52-week low is ₹292.2.

What is the TTM revenue of Solara Active Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Solara Active Pharma is ₹1,259 ( Cr.) .

About Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd.

The company is poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. It has hundreds of scientists working at its two R&D Centers and many API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities.

The company has a highly compliant manufacturing footprint spread over six large scale multi-product facilities. The company’s business is spread across several countries with extensive operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa.

Business area of the company

The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies.

Products and services